Grant Medical foundation Ruby Hall Clinic

Pune 411001

1 studies enrolling now · 13 studies all time

What they study most

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous Cell, Chemotherapy-Induced Nausea and Vomiting, Crohn's Disease, Hemophilia A With Inhibitor, Hemophilia B With Inhibitor, Idiopathic Thrombocytopenic Purpura, Neoplasm Metastasis, Rheumatoid Arthritis, Scleroderma, Systemic, Ulcerative Colitis

Studies at this site

• JNJ-90301900 (NBTXR3) Activated by Radiotherapy With or Without Cetuximab in LA-HNSCC — Recruiting now
• A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer — Recruiting now
• An Adaptive Phase 2a/2b Study of LY3871801 in Adult Participants With Rheumatoid Arthritis — Completed
• Filgotinib in Long-Term Extension Study of Adults With Ulcerative Colitis — Running, not enrolling
• A Study to Evaluate the Long-Term Efficacy and Safety of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 3) — Running, not enrolling
• A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer — Running, not enrolling
• A Study in People With Systemic Sclerosis to Test Whether Avenciguat (BI 685509) Has an Effect on Lung Function and Other Systemic Sclerosis Symptoms — Completed
• Filgotinib in Long-Term Extension Study of Adults With Crohn's Disease — Stopped early
• Filgotinib in the Induction and Maintenance of Remission in Adults With Moderately to Severely Active Crohn's Disease — Completed
• Study of Coagulation Factor VIIa Marzeptacog Alfa (Activated) in Subjects With Hemophilia A or B — Stopped early
• Study to Evaluate the Efficacy and Safety of Filgotinib in the Induction and Maintenance of Remission in Adults With Moderately to Severely Active Ulcerative Colitis — Completed
• IGIV Study for Chronic ITP Patients Ages 3-70 — Completed
• An Efficacy and Safety Study of Oral Netupitant and Palonosetron for the Prevention of Nausea and Vomiting — Completed